Overview

Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment. Additionally, this study would like to examine whether citalopram treatment is associated with an increase in the Gln/Glu ratio in the ACC from baseline to day 7 of treatment. In order to more fully examine baseline neurochemical and functional abnormalities in participants with MDD, we also seek to scan a group of age- and sex-matched non-depressed comparison individuals in order to perform between-group analyses of baseline neuroimaging measures.
Phase:
Phase 4
Details
Lead Sponsor:
Mclean Hospital
Treatments:
Antidepressive Agents
Citalopram
Dexetimide